5-HT3拮抗剂与对乙酰氨基酚联用增加术后阿片类药物消耗:一项医院登记研究
该医院登记研究纳入55,016例成人门诊全麻手术患者,探讨术中5-HT3拮抗剂是否影响对乙酰氨基酚与术后阿片消耗的关联。结果显示,未用5-HT3拮抗剂时对乙酰氨基酚使阿片消耗降低5.5%,而联用5-HT3拮抗剂时该效应消失(交互P=0.013)。提示使用对乙酰氨基酚预防疼痛时,5-HT3拮抗剂或应保留为术后恶心呕吐的补救用药。
要点
- 未用5-HT3拮抗剂时,对乙酰氨基酚降低术后阿片消耗5.5%。
- 联用5-HT3拮抗剂时,对乙酰氨基酚的阿片节省效应消失。
- 使用对乙酰氨基酚预防疼痛时,5-HT3拮抗剂可考虑留作止吐补救。
核心结论
- 联用5-HT3拮抗剂时未观察到对乙酰氨基酚降低术后阿片消耗的剂量依赖性关联。
研究设计与样本
- 医院登记研究,纳入2015至2022年马萨诸塞州三级医疗中心55,016例成人门诊全麻手术患者。
- 采用二分类暴露变量和多变量零膨胀负二项回归模型控制混杂因素。
主要发现
- 共3,166例(5.8%)仅用对乙酰氨基酚,15,438例(28.1%)仅用5-HT3拮抗剂,31,850例(57.9%)两者联用,4,562例(8.3%)两者均未用。
- 55,016例中16,640例(30.2%)接受阿片类药物,其中位术后阿片剂量为7.5 mg OME(IQR 7.5–14.3 mg OME);全体患者平均阿片剂量为3.2 mg OME(最大累积剂量20.4 mg OME)。
- 未用5-HT3拮抗剂者中,对乙酰氨基酚与阿片消耗降低5.5%相关(95%CI -9.6%至-1.4%;P=0.009;校正绝对差-0.19 mg OME;95%CI -0.33至-0.05;P=0.009)。
- 使用5-HT3拮抗剂者中,对乙酰氨基酚对阿片消耗无影响(校正绝对差0.00 mg OME;95%CI -0.06至0.05;P=0.93;交互P=0.013)。
临床怎么用
- 使用对乙酰氨基酚预防术后疼痛时,医师可考虑将5-HT3拮抗剂保留为术后恶心呕吐的补救用药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acetaminophen and 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are administered as standard prophylaxes for postoperative pain, nausea, and vomiting. Preclinical studies, however, suggest that 5-HT3 antagonists may compromise acetaminophen's analgesic effect. This hospital registry study investigates whether 5-HT3 antagonists mitigate the analgesic effect of prophylactic acetaminophen in a perioperative setting. METHODS: This study included 55,016 adult patients undergoing general anesthesia for ambulatory procedures at a tertiary healthcare center in Massachusetts from 2015 to 2022. Using binary exposure variables and a comprehensive selection of preplanned patient- and procedure-related covariates for confounder control, the authors investigated whether intraoperative 5-HT3 antagonists affected the association between pre- or intraoperative acetaminophen and postoperative opioid consumption, gauged by opioid dose in milligram oral morphine equivalents (OME) administered in the postanesthesia care unit. A multivariable, zero-inflated negative binomial regression model was applied. RESULTS: A total of 3,166 patients (5.8%) received only acetaminophen, 15,438 (28.1%) only 5-HT3 antagonists, 31,850 (57.9%) both drugs, and 4,562 (8.3%) neither drug. The median postanesthesia care unit opioid dose was 7.5 mg OME (interquartile range, 7.5 to 14.3 mg OME) among 16,640 of 55,016 (30.2%) patients who received opioids, and the mean opioid dose was 3.2 mg OME across all patients (maximum cumulative dose, 20.4 mg OME). Acetaminophen administration was associated with a -5.5% (95% CI, -9.6 to -1.4%; P = 0.009; adjusted absolute difference, -0.19 mg OME; 95% CI, -0.33 to -0.05; P = 0.009) reduction in opioid consumption among patients who did not receive a 5-HT3 antagonist, while there was no effect in patients who received a 5-HT3 antagonist (adjusted absolute difference, 0.00 mg OME; 95% CI, -0.06 to 0.05; P = 0.93; P for interaction = 0.013). CONCLUSIONS: A dose-dependent association of pre- or intraoperative acetaminophen with decreased postoperative opioid consumption was not observed when 5-HT3 antagonists were coadministered, suggesting that physicians might consider reserving 5-HT3 antagonists as rescue medication for postoperative nausea or vomiting when acetaminophen is administered for pain prophylaxis.
引用
- Ratajczak N, Munoz-Acuna R, Redaelli S, et al. Increased Postoperative Opioid Consumption in the Presence of Coadministration of 5-Hydroxytryptamine Type 3 Antagonists with Acetaminophen: A Hospital Registry Study. Anesthesiology. 2024. PMID: 38700445. doi:10.1097/ALN.0000000000005033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。